• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Shockwave Medical completes Neovasc acquisition

Shockwave Medical completes Neovasc acquisition

April 11, 2023 By Sean Whooley

Shockwave Medical to acquire NeovascShockwave Medical (Nasdaq:SWAV) announced today that it completed its $147 million acquisition of Neovasc.

In January, Shockwave announced an agreement to acquire all of the issued and outstanding common shares of Neovasc. The company paid $27.25 per share upfront by way of a statutory plan of arrangement.

The deal has an enterprise value of approximately $100 million. According to a news release, shareholders can receive up to an additional $12 per share if certain regulatory milestones are achieved within specified timeframes. Those deferred payments could reach approximately $47 million upon the achievement of future regulatory milestones.

Neovasc develops its Reducer system for addressing refractory angina. The Reducer has FDA breakthrough device designation and CE Mark. The company is currently enrolling patients in the COSIRA-II study, Shockwave said. Conducted under FDA investigational device exemption, COSIRA-II could support future FDA approval.

The Reducer alters blood flow within the myocardium of the heart. It also increases the perfusion of oxygenated blood to ischemic areas of heart muscle. Placement occurs through a minimally invasive, transvenous procedure.

Neovasc Reducer angina device
The Neovasc Reducer (Image from Neovasc)

Neovasc also reportedly had the Tiara mitral valve repair device under development in 2020.

More about Shockwave Medical’s acquisition of Neovasc

According to the initial announcement of the acquisition, Neovasc shareholders receive regulatory milestone payments in the form of a contingent value right (CVR) per common share. These arrive upon final FDA premarket approval to market the Neovasc Reducer. Each CVR pays:

  • $12 if achieved on or before Jun. 30, 2026
  • $8 if achieved during the period beginning on Jul. 1, 2026, and ending on Dec. 31, 2026
  • $4 if achieved during the period beginning on Jan. 1, 2027, and ending on Dec. 31, 2027.

As part of the agreement, Neovasc’s common shares will be delisted from the Toronto Stock Exchange. The company also requested that the Nasdaq market file a delisting application. Neovasc expects to terminate the registration of its common shares on the Nasdaq approximately 10 days after closing.

When the companies initially announced the deal, Neovasc CEO Fred Colen called it “good news” for stakeholders and the Reducer.

“The team at Shockwave has demonstrated an extraordinary ability to scale novel technologies and build value for patients, customers and investors, and we are thrilled to become a part of their organization,” he said.

Filed Under: Business/Financial News, Cardiovascular, Catheters, Featured, Mergers & Acquisitions, Wall Street Beat Tagged With: neovasc, Shockwave Medical

More recent news

  • Real-world data backs Route 92 reperfusion system
  • LivsMed unveils new surgical robot with telesurgery capabilities
  • JenaValve enrolls first patient in TAVR for AR study
  • HistoSonics expands insurance coverage for histotripsy treatment
  • Johnson & Johnson MedTech gets updated FDA nod for Varipulse PFA

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy